Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

Allergan's Restasis to Face Impending Generic Competition After Patent License Play Fails - Xtalks

Allergan settles Restasis litigation with Pfizer's InnoPharma as backlash mounts over tribal patent deal

CQ Researcher - Prescription Drug Costs

Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks

Does Allergan's Saint Regis Mohawk Tribe transactional move rip off consumers? - The IPKat

Allergan Mohawk Tribe Patent Deal

Pharma's contentious inter partes reviews come under Supreme Court scrutiny

Patent transfer to Mohawk tribe intended to stop generic drugs

Allergan CEO on patent deal: 'It wasn't desperation, it was tenacity

Allergan deal with Mohawk tribe casts patent shadow